Skip to content

Iron and Vitamin Supplementation in Hip/Knee Surgery

Emacrit Plus in Prosthetic Hip and Knee Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04880499
Enrollment
60
Registered
2021-05-10
Start date
2021-04-21
Completion date
2022-07-08
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Hip Arthropathy, Iron Poor Blood, Knee Arthropathy, Orthopedic Disorder

Brief summary

Randomized controlled trial to evaluate the efficacy of oral iron supplementation plus cofactors in reducing the prevalence of preoperative anemia in a cohort of 60 patients undergoing elective prosthetic hip or knee surgery.

Interventions

DIETARY_SUPPLEMENTIron plus folic acid, vitamin B2, B6, B12, C, and E

A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.

Sponsors

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Males and females * ASA 1, 2, or 3 * No neuropsychiatric conditions * Acceptance of informed consent * Elective prosthetic hip or knee surgery

Exclusion criteria

* ASA 4 * Present or past neuropsychiatric conditions * Hip or knee revision surgery * Use of iron as dietary supplement * Known erythrocytosis * Incompatible hypersensitivities * Iron metabolism disorders * Lymphoproliferative disorders

Design outcomes

Primary

MeasureTime frameDescription
Change of blood hemoglobin levelsBaseline and 60 days +/- 15 daysChange of hemoglobin concentration (g/dl) from baseline and after 60 days +/- 15 days

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026